We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$94.3M
Cap. Flow %
-2.4%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Miscellaneous 1.15%
4 Technology 0.53%
5 Real Estate 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ME
126
DELISTED
23andMe Holding Co
ME
– –
-33,050
Closed -$604K
CERE
127
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-5,041
Closed -$214K
FUSN
128
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-1,005,500
Closed -$9.66M
CBAY
129
DELISTED
Cymabay Therapeutics
CBAY
– –
-303,600
Closed -$7.17M
MRTX
130
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-500,000
Closed -$29.4M
HARP
131
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-1,304,127
Closed -$14.8M
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group's Q1 2024 filing shows 35 new, 30 increased, 17 reduced and 20 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M. The largest sale was CAVA Group, an estimated $295M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.